vidarabine phosphate and Adenocarcinoma

vidarabine phosphate has been researched along with Adenocarcinoma in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (25.00)	18.7374
1990's	2 (50.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Both, GW; Dane, A; Jeyakumar, G; Martiniello-Wilks, R; Mortensen, E; Russell, PJ; Shaw, JM; Voeks, DJ; Wang, XY	1
Clark, G; Hersh, M; Hutton, JJ; Kuhn, J; Phillips, J; Von Hoff, DD	1
Ashenhurst, JB; Benson, AB; Blough, RR; French, SL; Kilton, LJ; Schilsky, RL; Shiomoto, G; Wade, JL	1
Benson, AB; Blough, R; French, S; Greenberg, A; Johnson, P; Kilton, LJ; Shapiro, C; Weidner, L	1

Trials

2 trial(s) available for vidarabine phosphate and Adenocarcinoma

Article	Year
Phase II study of fludarabine phosphate for gastric adenocarcinoma. An Illinois Cancer Center trial. Investigational new drugs, 1994, Volume: 12, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Female; Humans; Injections, Intravenous; Male; Middle Aged; Stomach Neoplasms; Vidarabine Phosphate	1994
Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center study. Investigational new drugs, 1992, Volume: 10, Issue:3 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Vidarabine Phosphate	1992

Other Studies

2 other study(ies) available for vidarabine phosphate and Adenocarcinoma

Article	Year
Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease. The journal of gene medicine, 2004, Volume: 6, Issue:1 Topics: Adenocarcinoma; Adenoviridae; Animals; Animals, Genetically Modified; Antimetabolites, Antineoplastic; Disease Models, Animal; Escherichia coli; Female; Genetic Therapy; Infusions, Parenteral; Male; Mice; Mice, Inbred C57BL; Prodrugs; Prostate; Prostatic Neoplasms; Purine-Nucleoside Phosphorylase; Survival Analysis; Vidarabine Phosphate	2004
Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite. Cancer research, 1984, Volume: 44, Issue:9 Topics: Adenocarcinoma; Arabinonucleotides; Drug Evaluation; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Vidarabine; Vidarabine Phosphate	1984

Article

Year

Gene-directed enzyme prodrug therapy for prostate cancer in a mouse model that imitates the development of human disease.

The journal of gene medicine, 2004, Volume: 6, Issue:1

Topics: Adenocarcinoma; Adenoviridae; Animals; Animals, Genetically Modified; Antimetabolites, Antineoplastic; Disease Models, Animal; Escherichia coli; Female; Genetic Therapy; Infusions, Parenteral; Male; Mice; Mice, Inbred C57BL; Prodrugs; Prostate; Prostatic Neoplasms; Purine-Nucleoside Phosphorylase; Survival Analysis; Vidarabine Phosphate

2004

Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.

Cancer research, 1984, Volume: 44, Issue:9

Topics: Adenocarcinoma; Arabinonucleotides; Drug Evaluation; Female; Humans; Kinetics; Lung Neoplasms; Male; Neoplasms; Vidarabine; Vidarabine Phosphate

1984